
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is a key player in the refractive surgery market, and its signature product, the Implantable Collamer Lens (ICL), has shown strong demand in China, the key revenue generator for the company. With a clean Q1 base, solid early demand for the new EVO+ lens, and strong EBITDA numbers, Staar Surgical is on a strong footing and poised for growth in the coming years. However, without full visibility into the numbers and continued caution from management, there may be some potential risks to reaching its full potential.
Bears say
Staar Surgical is positioned for strong growth with a dominant market position in phakic IOLs, continued ex-China growth, and favorable industry dynamics, all of which will contribute to value creation. Despite some one-time costs, the company's improved adjusted EBITDA margin of 12% and management's confirmation of market acceptance of premium pricing for EVO+ suggest a potential for higher profits in the future. However, the company's heavy reliance on foreign sales and slow growth in its main product, ICL, may hinder its overall growth and profitability in the long run.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares